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Introduction:  Open  vial  vaccine  wastage  in multi-dose  vials  is a major  contributor  to  vaccine  wastage.
Although  switching  from  10-dose  vials  to 5-dose  vials  could  reduce  wastage,  a  higher  total  cost  could  be
triggered  because  smaller  vials  cost  more  to purchase  and  store.
Methods:  This  study  drew  ﬁeld  data  of  daily  session  sizes  in local  vaccination  facilities  from  Bangladesh,
India  (Uttar  Pradesh),  Mozambique,  and  Uganda,  and  used  Akaike  Information  Criteria  to  determine  the
best ﬁt statistical  distribution  across  various  clinic  types.  These  distributions  were  input to  estimate  the
vaccine  wastage  using  Lee’s  (2010)  model.  Inactivated  polio  vaccine  (IPV)  immunization  was  simulated
to  compare  the  costs  over  ten  years  with  10-dose  vials  versus  5-dose  vials.
Results:  By  switching  from  10-  to 5-dose  vials, the  observed  open  vial wastage  rate  due  to  vial size
preference  and  session  size  for IPV  was  reduced  from  0.25  to 0.11  in Bangladesh,  0.17  to 0.08  in  India  (Uttaression size Pradesh),  0.13  to 0.06  in  Mozambique,  and  0.09  to 0.04  in Uganda,  respectively.  The  cost  savings  realized
from  lower  IPV  wastage  did  not  offset  the  higher  costs  of  procurement  and  storage  costs  associated  with
smaller  dose  presentation.
Conclusion: While  our model  showed  that  switching  from  10-dose  vials to 5-dose  vials  of  IPV reduced
open  vial  wastage,  it was  not  cost-saving.
© 2014  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND. Introduction
One of the largest impediments to efﬁcient immunization is the
astage of opened and unopened vaccine vials [1]. As developing
ountries introduce new and expensive vaccines, there is a need to
nderstand factors that contribute to vaccine wastage so potential
olutions can be assessed.
Vaccine wastage is deﬁned by the World Health Organization
WHO) [2] as “loss by use, decay, erosion, or leakage or through
astefulness”, and can be calculated as the proportion of vac-
ine administered against vaccine issued [1]. Vaccine wastage falls
nto two categories: wastage in unopened vials and wastage in
pened vials. Wastage in unopened vials results from expiration,
hermo-instability, breakage, missing inventory, and other inciden-
al causes [3], and is generally a static rate [4].
∗ Corresponding author at: BD Health Economics and Outcomes Research, Franklin
akes, NJ, USA. Tel.: +1 201 847 7347; fax: +1 201 847 7489.
E-mail addresses: Wanfei yang@bd.com, yangwanfei@gmail.com (W.  Yang).
ttp://dx.doi.org/10.1016/j.vaccine.2014.09.057
264-410X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article unlicense  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Wastage in opened vials is much higher than in unopened vials
[5], and varies from facility to facility. It is related to many factors
including immersion of opened vials in water, uncertainty about
the sterility of prior withdrawals, thermal handling, and poor vac-
cine administration practices [1]. With the use of a multi-dose
vial (MDV), there is a risk of contamination every time a needle
is inserted into the vial. Furthermore, when a health care worker
(HCW) opens a MDV  and is unable to use the remainder before it
expires, excessive open vial wastage can occur at the clinic level
[6].
To address open vial wastage, the WHO  has a multi-dose vial
policy (MDVP) that permits vials of certain vaccines to remain open
for up to 4 weeks so long as certain criteria are met  regarding hand-
ling, administration, and storage [7]. Some local health programs
may  feel that they are unable to meet these conditions (for instance,
in rural vaccination clinics or outreach settings) and workers may
discard open vials after each clinic day. With certain vaccines, the
MDVP may  not apply [4,8].
For countries and clinic settings that cannot comply with the
WHO MDVP, there are two driving factors that inﬂuence open vial
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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accine wastage: (1) the session size of a vaccination facility, and
2) the vaccine vial size [8,9]. The larger the session size (the more
hildren who showed up for vaccination during one session), the
ewer the overall remaining doses.
One strategy that has been examined to help reduce open vial
astage is to lower the number of doses per vaccine vial [2,3].
 2012 study found that in primary care settings in urban India,
ial size is statistically signiﬁcantly related to vaccine wastage
10]. While switching to lower dose vials might reduce open vial
accine wastage, it will incur higher purchasing, manufacturing,
torage and vaccine delivery costs. Moreover, many new vaccines
ome at a higher price per dose than traditional vaccines, and thus
astage is more costly [11]. A 2009 study found that the optimal
ial size depends on country-speciﬁc wastage rates, and concluded
hat these critical data are missing for most GAVI eligible countries
12].
In 2010, Lee et al. [6] applied a mathematical model to capture
he vaccine wastage and associated economic impact of differ-
nt vial size strategies. Due to the lack of facility data in real-life
ettings, the paper assumed that session size follows a Poisson
istribution. The paper emphasized that in order to calculate the
xpected wastage rate, one needs to ﬁrst deﬁne the distribution of
ession size. No studies have since collected data on vaccine session
izes and deﬁned a statistical distribution to generate open vial
accine wastage as an output.
In our study, we used session size data from four countries to
evelop a realistic statistical model of open vial wastage rates and
heir associated costs. We  use the term “session size” in our study
o refer to the number of children who arrive at a given vacci-
ation session. There were two primary objectives to this study:
rst, to use session size data from four GAVI-eligible countries
o understand country-level factors that inﬂuence wastage in open
ials; second, to estimate the economic impact of switching to
maller dose vials.
The Strategic Advisory Group of Experts on Immunization
SAGE) recommended inactivated polio vaccine (IPV) to be
ntroduced to the routine immunization program by 2015 [13].
ecause the MDVP will likely not apply to IPV, we focused our study
n the case of IPV.
. Methods
Bangladesh, India (Uttar Pradesh), Mozambique, and Uganda
ere chosen to reﬂect various population sizes and urbanicity
mong developing countries in Africa and Asia (see Table 1). Session
ize data were collected from representative facilities in the four
ountries. IPV wastage and associated costs were examined in this
aper, though our model enables users to simulate different types
f vaccines in various presentation and dose schedules. Our model
ses a 1-dose schedule for IPV.
able 1
emographics of sample countries. We  collected data from Bangladesh, India (Uttar Prad
arge  populations and combination of different immunization session sizes.
Region Country Populationa
(Million)
Birth cohort
size (Million)b
Growth ra
cohort 201
Asia Bangladesh 157.6 Low (3) −0.02 
Asia  India 1260.5 High (27) −0.003 
Africa Mozambique 26.2 Low (1) 0.01 
Africa Uganda 38.3 Low (2) 0.06 
a GeoHive; population as of January 2014.
b GAVI alliance; birth cohort size.
c United Nations (2012). World population prospects: the 2012 revision.
d UNICEF; coverage rate using DTP3 as proxy: >80% high, 60–80% medium, <60% low; W
e World Bank estimates.
f GAVI; support plan for new vaccine introduction. (2014) 6643–6648
2.1. Data input
This study used data on session sizes to model populations
from Bangladesh, India (Uttar Pradesh), Mozambique, and Uganda.
The rural data from Bangladesh originated from four clinics in the
Sunamganj district, consisting of one large outpatient clinic, two
union health centers, and one subcenter. The urban data from
Bangladesh came from three urban subcenters, two urban HC
III clinics, and three large urban clinics (“HC” stands for “health
center”). The number of pentavalent vaccine doses administered
between January and December 2012 were counted at each session.
For India, we collected data on the number of DPT doses admin-
istered in two HC III clinics in the Basti district of Uttar Pradesh
from January to February 2012. There were no data available from
urban clinics in Uttar Pradesh.
The data from Mozambique came from 74 Centro Salud Rural
(CSR) 1 sessions, 49 CSR2 sessions, as well as 45 outreach sessions
from the Inhambane district of Mozambique in 2012. The number
of children receiving a pentavalent vaccine each day was recorded.
There were also no data available from urban clinics in Mozam-
bique.
The Ugandan data originated from the Service Provision
Assessment (SPA) Survey of 2007 that was collected by Macro
International [14]. After weighting, the survey provided a national
representative sample of all government health care facilities in
Uganda. Data were collected by site inspections and health record
review from 433 facilities providing immunization at HC-IIs, HC-
IIIs, HC-IVs, rural hospital settings and urban settings. The SPA
survey had sampling weights for each type of facility, so one can
produce estimates of the national count of each type of facility. The
counts of daily children arriving in facilities in the SPA data were
based on all children, not just children requesting immunization.
The estimated number of facilities in each country relied on
SPA data in Uganda [18], and Bangladesh [15]. Facility count esti-
mates for Mozambique were extrapolated on a population basis
from Inhambane province to all Mozambiquan provinces. Facility
count estimates for India were conﬁned to only rural Uttar Pradesh.
In each country or region, the daily session size data for each
clinic type was  determined by ﬁtting the parameters of various
distributions. A maximum likelihood algorithm to ﬁnd parame-
ters that minimized the root mean squared error between the
data and each candidate distribution was implemented in Palisades
@Risk Version 6.01. This algorithm provided three best-ﬁtting dis-
tributions with their associated Akaike Information Criterion (AIC)
scores and parameters. The distribution that had the lowest AIC
score was chosen as the best-ﬁt distribution at each type of clinic
to express the pattern of session size observed. The AIC was  prefer-
able to a chi-squared goodness of ﬁt test because it takes account
of the degrees of freedom and it could be implemented for discrete
data unlike the Kolmogorov–Smirnov test. (Please refer Table 2 for
all model inputs.)
esh), Mozambique, and Uganda, 4 GAVI eligible countries, to reﬂect both small and
te of birth
4–2024c
Current
coverage rated
Urbanicitye Year of IPV
introduction planf
High (96%) Rural (>70%) 2014
Medium (72%) Mixed (>65%) 2014
Medium (75%) Mixed (>60%) 2014
High (82%) Rural (>85%) 2014
HO/UNICEF estimates.
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Table  2
Model inputs table.
Country Clinic type Number of clinicsa,b,c,d Days open per monthe Distribution
Bangladesh HC II, rural 482 7 Neg Bin (26, 0.78)
HC  III, rural 13,494 1 Poisson (12.67)
HC  IV, rural 36,000 1 Neg Bin (14, 0.92)
SC  type II, urban 36,000 1 Poisson (33.83)
SC  type III, urban 36,000 1 Uniform (2, 7)
India  (Uttar Pradesh) Sub-center, HC III 20,521 7 Neg Bin (4,0.33)
Mozambique CSR  I, rural, ﬁxed 576 20 Neg Bin (2, 0.20)
CSR  I, rural, outreach 576 2 Neg Bin (2, 0.20)
CSR  II, rural, ﬁxed 432 20 Neg Bin (3, 0.16)
CSR  II, rural, outreach 432 2 Neg Bin (2, 0.20)
Uganda HC  II, rural, ﬁxed 285 5 Neg Bin (2, 0.24)
HC  II, rural, outreach 285 10 Geomet (0.06)
HC  III, rural, ﬁxed 154 8 Geomet (0.06)
HC  III, rural, outreach 154 4 Geomet (0.06)
HC  IV, rural, ﬁxed 26 12 Neg Bin (2, 0.11)
HC  IV, rural, outreach 26 6 Geomet (0.06)
Hospital, rural, ﬁxed 17 16 Geomet (0.04)
Hospital, rural, outreach 17 4 Geomet (0.06)
All,  urban, ﬁxed 9 12 Geomet (0.06)
All,  urban, outreach 9 0 0
Neg Bin stands for negative binomial.
a Collection of rural ﬁeld data and extrapolating to all other rural districts.
b For Uttar Pradesh facility counts come from a collection of ﬁeld data in two clinics in Uttar Pradesh and analysis of facility types using the data in the session size survey.
c For Mozambique, facility counts come from an analysis of facility types using HMIS data from Inhambane province and extrapolating to all provinces (other than Maputo
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d For Uganda, facility counts come from measure DHS, Uganda Service Provision 
e Analysis of session size data in each country.
.2. Vaccine wastage model assumptions
The model estimated the present value of the total number
f doses of IPV delivered and doses wasted from January 1, 2014
hrough December 31, 2023 in each of the country populations,
sing a discount rate of 3%. Coverage was assumed to remain at 92%
n each of the countries in a 10-year analytical horizon, based on
ecent data on DPT3 coverage [16]. Birth cohort growth or shrink-
ge was estimated based on UN medium variant projections and
as adjusted for background mortality [17]. In this model, HCWs
ere assumed to always discard a partially used vial at the end of
he session.
.3. Wastage
Following the model of Lee et al. [6], the number of vials opened
n a clinic at the end of one session (n) will depend upon the number
f children (d) who arrived at the clinic during the day.
 = Roundup
(
d
v
)
(1)
here d stands for the number of children coming for vaccination,
nd v is the vial size. Since session size is a major determinant of
accine wastage, we used our statistical model of session size to
enerate stochastic estimates of “d”. The doses wasted (w) at the
nd of one session was calculated using the modulo arithmetic of
ession size versus the vaccine vial size.
 = v − Mod[d, v] (2)
here the modulus function “Mod [d, v]” means “take the remain-
er of d/v”.
The wastage rate of the vaccine (wp) at one session is given by:
p = w (3)
n × v
To model the number of vials used and the number of doses
asted, we extrapolated country totals as the weighted sum of each
ype of clinic. If ni is the number of vials opened in the “ith” typement (2007).
of clinic, the annual number of vials opened in the country is given
as, summed over i:
Number of vials used per year =
∑
NiSini (4)
where Ni is the number of type “i” facilities in the country and Si
is the number of sessions per year for a type “i” facility. A similar
expression estimates the number of doses wasted.
Number of doses wasted per year =
∑
NiSiwi (5)
2.4. Cost
Given a procurement price of Pv dollars per vial, the acquisition
cost of vaccine per year is calculated as:
Cost of acquiring vaccine = Vials purchased × Pv (6)
Full cost of vaccine = Vials purchased × (Pv + CCv) , (7)
where CCv is cold-chain storage cost per vial
Full cost of wasted vaccine = doses wasted × (PD + CCD) (8)
where PD is the procurement price per dose, and CCD is cold-chain
storage cost per dose.
Cold-chain storage cost per dose was estimated using the 2012
WHO vaccine volume calculator [18]. This estimates that the cold
chain costs for a 10-dose vial is $0.03 per dose and 5-dose vials costs
$0.05 per dose.
2.5. IPV modeling and sensitivity analysis
The model speciﬁed in Eqs. (4) and (5) was used to depict two
policy options: (1) offering IPV in 10-dose vials and (2) offering IPV
in 5-dose vials. For each country and each policy option the model
ran 1000 replications drawing independently from the statistical
distributions of session size for all of the various types of clinics in
the country as speciﬁed in Eqs. (4) and (5). The baseline cost per
dose of the vaccine was assumed to be $2.48 per dose in 10-dose
vials, using the mean of the price range released by UNICEF [19],
6 ine 32 (2014) 6643–6648
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nd $2.98 per dose in 5-dose vials, which is a procurement price gap
f $0.50. As no price information is available for IPV 5-dose vials,
e carried out a univariate sensitivity analysis to vary the price gap
rom zero to a $1.00 per dose between 10- and 5-dose vials.
. Results
Our study found that session size varied signiﬁcantly within
nd across all four countries included in the analysis. Table 3 lists
he median session size and 25th to 75th percentile for different
ypes of healthcare centers in Bangladesh, India (Uttar Pradesh),
ozambique, and Uganda. Depending on whether the clinic set-
ing was urban, rural, outreach or ﬁxed, the median session size
aried between 3 and 15 children.
To predict session size in different clinical settings, session
ize ﬁeld data were used for statistical distribution ﬁtting. Fig. 1
hows the Akaike Information Criteria (AICs) score associated with
he best ﬁtting parameters within each statistical distribution
amily—the lower the AIC, the better the ﬁt. The negative binomial
amily offered the greatest number of best-ﬁt results compared to
he other three families, though as seen in Fig. 1, the AIC score of the
econd best-ﬁt did not differ greatly from the best-ﬁt in some cases.
he best-ﬁt distributions were parameterized for each clinic type
n each country and applied in the calculation of vaccine wastage.
Wastage in both 10-dose vials and 5-dose vials presentations
as calculated, indicating a lower wastage rate for using 5-dose
ials. Table 4 shows that by switching from 10-dose vials to 5-dose
ials, the wastage rate was reduced in all four countries.While using 5-dose vials produced a lower wastage rate, it
lso triggered an increase in the per-dose fully loaded cost, which
ncluded the procurement costs, cold-chain costs, and cost of open
ial wastage. Fig. 2 shows the distributions of the present values of
able 3
ession size variations by country and clinic type. The various clinic types in each of the fo
C:  health clinics, HC II: large outpatient clinic, HC III: primary health center, HC IV: sub 
Session size median (25th, 75th percentile)
Bangladesh Mozambique 
Clinic type Session size Clinic type Session size 
Rural HC II 7 (5, 9) CSR I 7 (3, 11) 
HC  III 12 (10, 15) CSR II 13 (8, 20) 
HC  IV 4 (3, 6) Outreach 6 (3, 11) 
Urban HC  III 6 (4, 9) 
Sub-centers 3 (2, 5)
Large 9 (6, 13)
able 4
astage rates of inactive polio vaccine with 25th and 75th percentiles. The wastage rates
ill  yield a lower wastage rate.
Wastage rates with inactive polio vaccine median (25th, 75th percentile)
Bangladesh India (Uttar 
10-Dose vials 0.25 (0.24–0.26) 0.17 (0.15–
5-Dose  vials 0.11 (0.11–0.12) 0.08 (0.07–
Reduction in wastage 56% 53% 
able 5
edian present value of total program costs in a 10-year analytical horizon. The table 
ountries when the price gap per dose between a 5- and a 10-dose vial is $0.50.
Present value of total program costs in 10-years median
Bangladesh India (Uttar P
10-dose vials $220,083,463 $350,291,136
5-dose vials $224,594,252 $382,743,572Criteria (AICs) associated with the best ﬁtting parameters within each statistical
distribution family. The best ﬁt distribution is determined by the lowest AIC score
in  each clinic type.
fully loaded per dose costs in a 10-year analytical horizon for IPV
with a procurement price of $2.48 per dose in 10-dose vials and
a price gap of $0.50 per dose in 5-dose vials in Bangladesh, India
(Uttar Pradesh), Mozambique, and Uganda. Moreover, the median
total program costs increased when switching from a 10-dose vial
presentation to a 5-dose vial presentation (see Table 5).
The breakeven point analysis identiﬁed the per-dose price gap,
where the fully loaded cost per dose of vaccine would be the same
for a 5-dose vial and a 10-dose vial, taking into consideration the
procurement price, associated cold-chain costs, and wastage. This
analysis showed that the 5-dose vials’ breakeven point occurred at a
$0.45, $0.25, $0.20, and $0.10 per dose procurement price gap over
10-dose vials in Bangladesh, India (Uttar Pradesh), Mozambique,
and Uganda respectively.
ur countries as well as median session size and 25th and 75th percentiles are listed.
center and CSR: center salud rural.
India (Uttar Pradesh) Uganda
Clinic type Session size Clinic type Session size
HC III 5 (3, 9) HC II 5 (3, 9)
HC III 6 (4, 9) HC III 11 (4, 23)
HC IV 13 (7, 21)
Hospital 15 (6, 30)
Urban 10 (4, 21)
 estimated by the model indicate that switching from 10-dose vials to 5-dose vials
Pradesh) Mozambique Uganda
0.20) 0.13 (0.12–0.15) 0.09 (0.08–0.10)
0.10) 0.06 (0.06–0.07) 0.04 (0.04–0.05)
53% 44%
demonstrates the present value of IPV total program cost in 10 years in the four
radesh) Mozambique Uganda
 $53,497,701 $97,492,755
 $59,770,274 $111,760,345
W.  Yang et al. / Vaccine 32 (2014) 6643–6648 6647
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. Discussion
This is the ﬁrst study of its kind to generate estimates of open vial
accine wastage from session size data collected at various types of
ealthcare clinics. In our model, open vial wastage estimates were
erived from probability distributions ﬁtted to session size data.
o account for uncertainty, we ran 1000 replications drawing from
he modeled session size distributions and reported the median in
ur results. We  chose to report the median because the negative
inomial is a skewed distribution and the cost estimates were also
kewed, as shown in Fig. 2. The study directly addressed the need
o validate the assumption of session size distribution in both Lee’s
aper and other literature [8].
Our study simulated different vial size strategies that have
een evaluated in the literature [8]. Though our model found
hat open vial wastage decreased when using 5-dose vials versus
0-dose vials, it did not disappear altogether, and still bore a signif-
cant cost. Moreover, there is a potential barrier to implementing
ower dose vials that our model did not consider, which is storagedose vials in Bangladesh, India (Uttar Pradesh), Mozambique and Uganda.
capacity [20]. A recent analysis conducted by researchers at WHO
and PATH found that 7 of the 20 GAVI-eligible countries evaluated
had reached their national storage capacity limits by 2012, and by
2015 a total of 11 of the 20 were projected to exceed 100% national
store [3].
The univariate sensitivity analysis identiﬁed different break-
even points in the four countries included in this study. Our analysis
found that a 5-dose vial policy would be about 2% more expensive in
Bangladesh, about 9% more in India (Uttar Pradesh), about 12% more
in Mozambique, and about 14% more in Uganda, accounting for both
the savings from lower wastage and the higher cost of acquisition.
Because of the variability of session sizes both across and within
countries, some countries saw greater savings than others when
using a 10-dose vial compared to a 5-dose vial. In countries that
have more urban clinics with large session sizes, there was less
open vial wastage, and as a result there was  a greater difference in
total program costs when using 10-dose vials versus 5-dose vials.
Our analysis indicates that policy makers should consider country-
speciﬁc situations when making the optimal choice on vial size.
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A potential limitation of this paper is that our model did not take
nto consideration the proportion of wastage due to over procure-
ent of vaccines and closed-vial wastage. Moreover, due to paucity
f data, our model was not able to estimate the proportion of open
ial wastage due to contamination, exposure to extreme tempera-
ures and improper administration techniques. For these reasons,
he wastage rates yielded in our model are conservative estimates.
Another potential limitation of this paper is that our model did
ot capture the impact of vaccine vial size on the coverage rate.
accine policy makers may  encounter a concern that the choice of
ial size could affect vaccine coverage due to a HCW’s fear of open-
ng a new vial. For example, in the event that an eleventh child
hows up toward the end of a vaccination session, it is possible
hat a HCW will be less reluctant to open a 5-dose vial than a 10-
ose vial. If the clinic was equipped with only 10-dose vials, some
taff might prefer to reschedule a vaccination to avoid wastage, and
hus take a risk that the child will not return [21]. Additionally, the
odel assumed that 5-doses of vaccine are packaged in a slightly
maller vial size compared to 10-doses of vaccine, when it is possi-
le that the actual size of the vial does not change depending on the
ose. Furthermore, we did not take into account micro cold chain
osts in our model, including the cost to buy and/or run additional
efrigerators. These two prior assumptions could have led to an
nderestimation of cold chain costs. Moreover, we  assumed that
he whole country was using the same vial size when we  modeled
pen vial wastage, and did not examine possibilities of choosing a
ombination of 10-, 5-, and single-dose vials.
Finally, we designed a dynamic model based on Lee’s method-
logy and populated it with ﬁeld data, which can enable
ecision-makers in the four countries to simulate different vacci-
ation scenarios. The negative binomial distribution was  typically
he best ﬁtting distribution by the Akaike Information Criteria;
owever when we compared results using Poisson as the dis-
ribution pattern with parameters generated from @Risk in each
ountry, the estimated vial wastage did not vary much. In no case
id the choice of arrival distribution alter the identiﬁcation of the
ost cost-effective choice of wastage control strategy. Our ongo-
ng research is exploring the mathematical reason why  models of
pen-vial wastage are relatively insensitive to the assumptions
bout arrival distribution. The current results conﬁrm that col-
ecting detailed data on the arrival distribution is primarily useful to
chieve precise estimates of expected wastage, but identifying the
ost cost-effective vial size strategy is not sensitive to assumptions
ithin the choices of Poisson, or negative binomial distribution.
In summary, our study found that open vial wastage can be low-red by reducing MDVs from 10-dose vials to 5-dose vials. In the
ase of IPV, this reduction in wastage did not lead to a reduction in
otal program costs, and a 5-dose vial presentation increased the
ost of vaccine delivery compared to a 10-dose vial presentation.
[ (2014) 6643–6648
Due to the dynamic nature and ﬂexibility of our model design, vari-
ous vaccines, vial sizes, and dose schedules for these countries may
be modeled to examine the trade-offs between vial sizes, wastage
rates and total program costs. This tool can serve to assist pol-
icy makers in weighing several complex issues in effective vaccine
stewardship.
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